How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis
- PMID: 17053529
- DOI: 10.1097/01.hjh.0000249685.58370.28
How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis
Abstract
Objective: To quantify the effect of first-line antihypertensive treatment with beta-blockers on mortality, morbidity and withdrawal rates, compared with the other main classes of antihypertensive agents.
Methods: We identified eligible trials by searching the Cochrane Controlled Trials Register, Medline, Embase, reference lists of previous reviews, and contacting researchers. We extracted data independently in duplicate and conducted meta-analysis by analysing trial participants in groups to which they were randomized, regardless of subsequent treatment actually received.
Results: Thirteen trials with 91,561 participants, meeting inclusion criteria, compared beta-blockers to placebo (four trials; n = 23,613), diuretics (five trials; n = 18,241), calcium-channel blockers (CCBs) (four trials; n = 44,825), and renin-angiotensin system (RAS) inhibitors, namely angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (three trials; n = 10,828). Compared to placebo, beta-blockers reduced the risk of stroke (relative risk 0.80; 95% confidence interval 0.66-0.96) with a marginal fall in total cardiovascular events (0.88, 0.79-0.97), but did not affect all-cause mortality (0.99, 0.88-1.11), coronary heart disease (0.93, 0.81-1.07) or cardiovascular mortality (0.93, 0.80-1.09). The effect on stroke was less than that of CCBs (1.24, 1.11-1.40) and RAS inhibitors (1.30, 1.11-1.53), and that on total cardiovascular events less than that of CCBs (1.18, 1.08-1.29). In addition, patients on beta-blockers were more likely to discontinue treatment than those on diuretics (1.80; 1.33-2.42) or RAS inhibitors (1.41; 1.29-1.54).
Conclusion: Beta-blockers are inferior to CCBs and to RAS inhibitors for reducing several important hard end points. Compared with diuretics, they had similar outcomes, but were less well tolerated. Hence beta-blockers are generally suboptimal first-line antihypertensive drugs.
Similar articles
-
Beta-blockers for hypertension.Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002003. doi: 10.1002/14651858.CD002003.pub2. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2012 Aug 15;(8):CD002003. doi: 10.1002/14651858.CD002003.pub3. PMID: 17253471 Updated. Review.
-
Beta-blockers for hypertension.Cochrane Database Syst Rev. 2017 Jan 20;1(1):CD002003. doi: 10.1002/14651858.CD002003.pub5. Cochrane Database Syst Rev. 2017. PMID: 28107561 Free PMC article. Review.
-
Beta-blockers for hypertension.Cochrane Database Syst Rev. 2012 Nov 14;11:CD002003. doi: 10.1002/14651858.CD002003.pub4. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2017 Jan 20;1:CD002003. doi: 10.1002/14651858.CD002003.pub5. PMID: 23152211 Updated. Review.
-
Beta-blockers for hypertension.Cochrane Database Syst Rev. 2012 Aug 15;(8):CD002003. doi: 10.1002/14651858.CD002003.pub3. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2012 Nov 14;11:CD002003. doi: 10.1002/14651858.CD002003.pub4. PMID: 22895924 Updated. Review.
-
First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.Cochrane Database Syst Rev. 2015 Jan 11;1:CD008170. doi: 10.1002/14651858.CD008170.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2018 Nov 14;11:CD008170. doi: 10.1002/14651858.CD008170.pub3. PMID: 25577154 Updated. Review.
Cited by
-
Autonomic control of ventricular function in health and disease: current state of the art.Clin Auton Res. 2023 Aug;33(4):491-517. doi: 10.1007/s10286-023-00948-8. Epub 2023 May 11. Clin Auton Res. 2023. PMID: 37166736 Free PMC article. Review.
-
The impact of β-blockers on the central and delta systolic pressures in a real-world population with treated hypertension: A cross-sectional study.Health Sci Rep. 2022 Nov 25;5(6):e948. doi: 10.1002/hsr2.948. eCollection 2022 Nov. Health Sci Rep. 2022. PMID: 36447568 Free PMC article. No abstract available.
-
Impact of medication on blood transcriptome reveals off-target regulations of beta-blockers.PLoS One. 2022 Apr 21;17(4):e0266897. doi: 10.1371/journal.pone.0266897. eCollection 2022. PLoS One. 2022. PMID: 35446883 Free PMC article.
-
Benefits and adverse events of melatonin use in the elderly (Review).Exp Ther Med. 2022 Mar;23(3):219. doi: 10.3892/etm.2022.11142. Epub 2022 Jan 14. Exp Ther Med. 2022. PMID: 35126722 Free PMC article. Review.
-
Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients: A Large-Scale Multicenter Observational Study.Hypertension. 2021 May 5;77(5):1528-1538. doi: 10.1161/HYPERTENSIONAHA.120.16402. Epub 2021 Mar 29. Hypertension. 2021. PMID: 33775125 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical